We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Genentech's glyco-engineered antibody to succeed Rituxan.
- Authors
Ratner, Mark
- Abstract
The article focuses on the Gazyva (obinutuzumab), the successor of pharmaceutical company Genentech Inc. to its long-time blockbuster drug Rituxan (rituximab), which gained approval from the U.S. Food and Drug Administration (FDA). Topics include the efficiency of Gazyva in chronic lymphocytic leukemia (CLL) treatment, the development of the drug, and the benefits of type 1 antibodies in engaging complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
- Subjects
DRUG approval; UNITED States. Food &; Drug Administration; GENENTECH Inc.; RITUXIMAB; CHRONIC lymphocytic leukemia treatment; CELL-mediated cytotoxicity; ANTIBODY-dependent cell cytotoxicity
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 1, p6
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0114-6b